| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/29/1994 | WO1994021817A1 Calpain inhibitors to treat programmed cell death |
| 09/29/1994 | WO1994021813A1 Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
| 09/29/1994 | WO1994021809A1 Monocyte or macrophage migration factor |
| 09/29/1994 | WO1994021808A1 Process for preparing cancer vaccines |
| 09/29/1994 | WO1994021807A2 Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| 09/29/1994 | WO1994021806A1 Delivery system controlled through factors associated with hiv and cell |
| 09/29/1994 | WO1994021800A2 Protein tyrosine phosphatase ptp-s31 |
| 09/29/1994 | WO1994021799A1 USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES |
| 09/29/1994 | WO1994021798A1 Stimulation of immune response by viral protein |
| 09/29/1994 | WO1994021797A1 Nucleic acid pharmaceuticals |
| 09/29/1994 | WO1994021792A2 Inhibition of selected tumor growth with recombinant viral vectors |
| 09/29/1994 | WO1994021791A1 Agents for the prevention and treatment of breast cancer |
| 09/29/1994 | WO1994021781A2 Extracellular signal-regulated kinase, sequences, and methods of production and use |
| 09/29/1994 | WO1994021688A1 Method of decoloring human serum albumin |
| 09/29/1994 | WO1994021685A1 Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition |
| 09/29/1994 | WO1994021682A1 Selective crosslinking of hemoglobins by oxidized, ring-opened saccharides |
| 09/29/1994 | WO1994021680A1 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
| 09/29/1994 | WO1994021679A1 Inhibitor of vascular endothelial cell growth factor |
| 09/29/1994 | WO1994021677A1 Aza cyclohexapeptide compounds |
| 09/29/1994 | WO1994021676A1 IgE ISOFORMS AND METHODS OF USE |
| 09/29/1994 | WO1994021675A2 T cell epitopes of ryegrass pollen allergen |
| 09/29/1994 | WO1994021674A1 Polypeptide bombesin antagonists |
| 09/29/1994 | WO1994021673A1 Alpha-ketoamide derivatives as inhibitors of thrombosis |
| 09/29/1994 | WO1994021672A1 Novel antimicrobial peptides from bovine neutrophils |
| 09/29/1994 | WO1994021671A1 Adipocyte differentiation inhibitor peptide and adipocyte differentiation inhibitor containing said peptide as active ingredient |
| 09/29/1994 | WO1994021660A1 Cloned human alpha1c adrenergic receptor |
| 09/29/1994 | WO1994021607A1 New heterocyclic compounds, their preparation and their use |
| 09/29/1994 | WO1994021604A1 Prodrug derivatives of enzyme inhibitors with hydroxyl groups, methods of preparing them and their use |
| 09/29/1994 | WO1994021602A1 Urea derivatives useful as platelet aggregation inhibitors |
| 09/29/1994 | WO1994021300A2 Novel agent for controlling cell activity |
| 09/29/1994 | WO1994021295A1 Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells |
| 09/29/1994 | WO1994021294A1 Method of treating tumors with antibodies |
| 09/29/1994 | WO1994021292A1 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| 09/29/1994 | WO1994021288A1 Composition and method for reducing toxicity of biologically-active factors |
| 09/29/1994 | WO1994021286A1 Composition for oral administration of peptides |
| 09/29/1994 | WO1994021285A1 New use of a combination of verapamil and trandolapril |
| 09/29/1994 | WO1994021284A1 Therapeutic formulation and method |
| 09/29/1994 | WO1994021283A1 Method for inhibiting pulmonary oxygen toxicity using manganese superoxide dismutase |
| 09/29/1994 | WO1994021282A1 Pharmaceutical compositions comprising a ligand complexed with a soluble receptor |
| 09/29/1994 | WO1994021281A1 Polymer-polypeptide composition and method |
| 09/29/1994 | WO1994021279A1 Nutrient formulations and methods of treating malnutrition in aids |
| 09/29/1994 | WO1994021278A1 Potassium channel blocking compounds and their use |
| 09/29/1994 | WO1994021277A1 Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
| 09/29/1994 | WO1994021276A1 Agent for preventing and treating digestive mucosal disorders |
| 09/29/1994 | WO1994021275A1 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine |
| 09/29/1994 | WO1994021274A1 Synergistic combination of ethambutol and a glycopeptide antibiotic |
| 09/29/1994 | WO1994021273A2 USE OF ANGIOGENINE, AND/OR α1-MICROGLOBULINE AND/OR COMPLEMENTARY FACTOR D FOR LIMITING PROTEIN SECRETION |
| 09/29/1994 | WO1994021272A1 A method for treating microbial infection in an animal by administering a composition comprising lif and a cytokine |
| 09/29/1994 | WO1994021271A1 Methods and compositions for inducing phase separation of epithelial lipid bilayers |
| 09/29/1994 | WO1994021270A1 Use of platelet factor 4 to treat inflammatory diseases |
| 09/29/1994 | WO1994021245A1 Use of carnosine or a combination with urocanic acid for treatment of photodermatoses |
| 09/29/1994 | WO1994021243A1 Novel metal binding agents, and methods and compositions for their use to treat metal toxicity |
| 09/29/1994 | WO1994021242A1 Methods for the treatment of osteoporosis |
| 09/29/1994 | WO1994021240A2 Superparamagnetic particles, process for producing the same and their use |
| 09/29/1994 | WO1994021238A1 IgE-, IgE DEPENDENT HISTAMINE RELEASING FACTOR |
| 09/29/1994 | WO1994021235A1 Enhanced circulation effector composition and method |
| 09/29/1994 | WO1994021126A1 Nucleic acid coding for a tumor rejection antigen precursor |
| 09/29/1994 | WO1994021115A1 Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy |
| 09/29/1994 | WO1994018316A3 Apolipoprotein b mrna editing protein compositions and methods |
| 09/29/1994 | WO1994016094A3 Recombinant anti-vla4 antibody molecules |
| 09/29/1994 | WO1994015962A3 Derivatized calcitonins |
| 09/29/1994 | WO1994015958A3 Peptide inhibitors of cell adhesion |
| 09/29/1994 | WO1994013800A3 Mk protein preparation and use in cell culture |
| 09/29/1994 | WO1994011522A3 Vector for the expression of therapy-relevant genes |
| 09/29/1994 | WO1994011490A3 Products of the inhibition of advanced glycosylation |
| 09/29/1994 | DE4309815A1 Method for isolating and using guanylate cyclase-activating peptide I (GAP-I) |
| 09/29/1994 | DE4309517A1 Process for the preparation of a stabilised streptokinase lyophilisate |
| 09/29/1994 | CA2159085A1 Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy |
| 09/29/1994 | CA2158989A1 Alpha-ketoamide derivatives as inhibitors of thrombosis |
| 09/29/1994 | CA2158939A1 Protein tyrosine phosphatase ptp-s31 |
| 09/29/1994 | CA2158658A1 Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition |
| 09/29/1994 | CA2158655A1 Process for preparing cancer vaccines |
| 09/29/1994 | CA2158647A1 Conjugate containing botulinum toxin translocation and effector domains and heterologocus binding domain for the targeted control of cell activity |
| 09/29/1994 | CA2158564A1 Parvovirus receptors and methods of use |
| 09/29/1994 | CA2158546A1 Inhibition of selected tumor growth with recombinant viral vectors |
| 09/29/1994 | CA2158461A1 Stimulation of immune response by viral protein |
| 09/29/1994 | CA2158345A1 Cloned human alpha 1c adrenergic receptor |
| 09/29/1994 | CA2158252A1 Delivery system controlled through factors associated with hiv and cell |
| 09/29/1994 | CA2158148A1 Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| 09/29/1994 | CA2158051A1 Potassium channel blocking compounds and their use |
| 09/29/1994 | CA2157785A1 Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4 |
| 09/29/1994 | CA2157758A1 Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine |
| 09/29/1994 | CA2157596A1 T cell epitopes of ryegrass pollen allergen |
| 09/29/1994 | CA2155842A1 Novel heterocycles, their preparation and their use |
| 09/29/1994 | CA2155739A1 Novel antimicrobial peptides from bovine neutrophils |
| 09/29/1994 | CA2135893A1 Agent for preventing and treating digestive mucosal disorders |
| 09/28/1994 | EP0617127A1 Antigenic epitopes on B cell-bound IgE Immunoglobulins |
| 09/28/1994 | EP0617126A2 Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor |
| 09/28/1994 | EP0617125A2 A novel transport protein gene from the Huntington's disease region |
| 09/28/1994 | EP0617122A1 Dna fragment which codes for tumor cell proliferation inhibiting factor |
| 09/28/1994 | EP0616814A1 Compositions for controlled release of biologically active TGF - beta |
| 09/28/1994 | EP0616812A1 Combination with anti-hormonal compounds and binding molecules for the treatment of cancer |
| 09/28/1994 | EP0616811A1 Cell-free T cell antigen receptor and its clinical utilities |
| 09/28/1994 | EP0616803A2 Method for enhancing T-cell count |
| 09/28/1994 | EP0616641A1 Humanized b-b10, an anti-il2 receptor antibody |
| 09/28/1994 | EP0616615A1 Human interleukin-8 analogs |
| 09/28/1994 | EP0616614A1 Compositions and methods for inhibiting elastase |
| 09/28/1994 | EP0616613A1 Fragments of prion proteins |
| 09/28/1994 | EP0616537A1 CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS |
| 09/28/1994 | EP0616536A1 INHIBITING TRANSFORMING GROWTH FACTOR $g(b) TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |